LUME-Meso trial in malignant pleural mesothelioma fails endpoint

26 September 2018
2019_biotech_test_vial_discovery_big

Germany’s Boehringer Ingelheim yesterday announced that the Phase III LUME-Meso trial did not meet its primary endpoint of progression-free survival (PFS) [ NCT01907100].

In the LUME-Meso trial, patients with unresectable, epithelioid malignant pleural mesothelioma (MPM) were treated with nintedanib in combination with standard-of-care chemotherapy pemetrexed/cisplatin, compared to chemotherapy alone.

Complete study results were presented as an oral presentation at the IASLC 19th World Conference on Lung Cancer (WCLC 2018) and can be found here.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology